From: Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Variable
χ2
P value
Age, years
3.0
0.84
Disease duration, years
0.79
0.37
DAS28-ESR at baseline
1.01
0.31
HAQ-DI at baseline
1.48
0.22
MTX dose, mg weekly
0.26
0.61
PSL dose, mg daily
0.73
0.39
Prior use of biologics
5.7
0.017